Clinical Trial Detail

NCT ID NCT02962063
Title Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

Therapies

Carboplatin + Durvalumab + Paclitaxel

Age Groups: senior adult

No variant requirements are available.